Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
Status:
Recruiting
Trial end date:
2023-09-27
Target enrollment:
Participant gender:
Summary
This study is collecting post-marketing information on the safety and effectiveness of
Ventavis under the routine clinical practice for patients with PAH